Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response broadly matches the labeled indication (reduce blood pressure when oral therapy is not feasible/desirable) and general IV titration concept, but includes multiple unsupported/overly specific context claims (e.g., “urgent settings,” “fine control,” “during or after surgery,” “other critical-care situations”) that are not stated in the provided label text. Several safety/administration details from the label (monitoring/rebound, administration line separation, max infusion limitations, transition strategy, contraindications) are omitted but not directly requested by the listed claims.
Category Scores
Accurate Statements
Cleviprex (clevidipine) is an intravenous blood-pressure medicine.
Label 2 (Dosage and Administration): intended for intravenous use.
Cleviprex is used to quickly lower blood pressure in adults.
Label 1 (Indications and Usage): reduction of blood pressure when oral therapy not feasible/desirable; Label 12.2: rapid onset in perioperative patient population; no label text in prompt limiting to adults explicitly, but no contrary statement in provided sections.
Cleviprex is used when oral treatment is not practical or not appropriate.
Label 1 (Indications and Usage): when oral therapy is not feasible or not desirable.
Cleviprex is designed for quick titration because it is given through an IV.
Label 2.2: titrate to achieve desired blood pressure reduction; Label 12.2: onset within 2-4 minutes after starting infusion.
Cleviprex can be adjusted rapidly by clinicians to reach the target blood pressure.
Label 2.2: titrate; dose may be doubled at short intervals initially; individualized dosage depending on response.
Cleviprex is used for short-term, controlled lowering of blood pressure in acute settings.
Supported indirectly by Label 2.2 monitoring/transition guidance and Label 12.2 offset within 5-15 minutes after stopping; no explicit “acute settings” phrasing in provided label, but nothing contradicts short-term use in infusion context.
Cleviprex is not for long-term maintenance therapy.
Label 2.2: discontinue or titrate downward while appropriate oral therapy is established (implying transition off infusion rather than maintenance); label does not explicitly say “maintenance therapy,” but the provided instructions support non-maintenance positioning.
Unsupported Statements
Cleviprex is used as a controlled, rapid-acting option in urgent settings.
The provided label text does not mention “urgent settings.” It describes IV titration and rapid onset, but the specific “urgent settings” framing is not supported.
Cleviprex is used in urgent settings where doctors need fine control of blood pressure.
The provided label does not discuss “fine control” or that use is for that specific clinical need.
Cleviprex is commonly used in hospital settings for patients who need immediate blood-pressure reduction.
The provided label text does not state frequency or “commonly used.” It also does not claim hospital-wide common usage.
Cleviprex is used during or after surgery, including cardiovascular surgery, to help manage acute hypertension.
The provided label sections include a “Perioperative Hypertension” study, but the response specifies “including cardiovascular surgery” and “after surgery” and “acute hypertension,” which are not explicitly stated in the provided label text.
Cleviprex is used in other critical-care situations where rapid, short-term control of blood pressure is required.
The provided label text in the prompt does not use “critical-care situations” wording.
Cleviprex is used to quickly lower blood pressure in adults.
The label sections provided emphasize perioperative/specific trials but the prompt does not explicitly state “adults” in the provided indication section; no adult-only restriction is shown in the excerpt. This is treated as partially unsupported wording rather than a direct contradiction.
Contradictions
Low
AI Statement
Cleviprex can be adjusted rapidly by clinicians to reach the target blood pressure.
Label Reference
No direct contradiction found.
Important Omissions
Continuous monitoring of blood pressure and heart rate during infusion and until vital signs are stable; rebound hypertension monitoring for at least 8 hours after stopping prolonged infusions not transitioned to other therapies.
Importance:
Moderate
Administration constraints: single-use product; do not use if contamination suspected; use within 12 hours after stopper punctured; do not administer in the same line as other medications.
Importance:
Moderate
Label dosing precision elements: initial dose (1-2 mg/hour), titration interval specifics, maximum infusion limits, lipid load restriction, and limited experience beyond 72 hours.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the core indication and general IV titration are supported, the response omits multiple label-based monitoring and administration requirements and adds unsupported specificity about clinical contexts (“urgent,” “common,” “cardiovascular surgery,” “critical care”). Those omissions could contribute to incomplete safe-use framing if used as guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Unsupported contextual claims (urgent/critical-care/specific surgery types) and missing label safety/administration details (monitoring/rebound, line separation, single-use handling, dosing limits).
Suggested Improvement
Restrict claims to the label’s stated indication (BP reduction when oral therapy not feasible/desirable) and IV titration concept; add or preserve label-required monitoring (including rebound monitoring after prolonged infusions), and key administration/in-line handling and use/contamination timing requirements.